Cardioprotective Effects of GLP-1 and Their Mechanisms

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Ischaemic heart disease is the most common cause of death in the UK. Glucagon-like peptide-1 (GLP-1) has been demonstrated to protect the heart when it is deprived of blood supply (ischaemia). The mechanism for this protection is not clear. Similar protection occurs with ischaemic conditioning of the heart, which is dependent on potassium channel opening.

The investigators intend to establish whether GLP-1 mediated protection shares a similar mechanistic pathway. In order to do this the investigators will measures pressure--volume loops generated in the main pumping chamber of the heart at the time of a percutaneous coronary intervention (stenting). Patients will be allocated to GLP-1 alone, GLP-1 with glibenclamide (a potassium channel blocking medication approved for human use), saline control or glibenclamide alone.

The investigators hypothesis is that the effect of GLP-1 will be abrogated by use of glibenclamide.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Papworth Hospital NHS Foundation Trust
• Treatments: Glucagon; Glucagon-Like Peptide 1; Glyburide

Criteria

Inclusion Criteria:

• Age over 18

• Able to give informed consent

• Elective percutaneous intervention for a single vessel coronary stenosis

• Normal left ventricular function

Exclusion Criteria:

• Severe Co-morbidity

• Type 2 Diabetes Mellitus

• Nicorandil, Sulphonylureas, DPP4 inhibitors, GLP-1 agonists or Insulin use

• Women of child bearing age

• Myocardial infarction in previous three months

• Previous coronary artery bypass grafts